Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Prolonged exposure to high-dose atorvastatin may suppress prostate cancer proliferation

23 Nov 2018

Long exposure to atorvastatin appears to slightly reduce prostate cancer proliferation rates in patients scheduled for radical prostatectomy, according to a recent study.

The study included 158 statin-naïve prostate cancer patients who were randomly assigned to receive either 80 mg atorvastatin (n=80; median age 64 years) or placebo (n=78; median age 63 years) daily for a median duration of 27 days. Baseline lifestyle habits, comorbidities and tumour characteristics were comparable between both treatment arms.

Overall, no significant difference in the median levels of tumour proliferation marker Ki-67 was observed between the two treatment arms (placebo vs atorvastatin: 1.98 vs 1.78; percent difference, –10 percent; p=0.9). However, effect modification by exposure time was statistically significant (p=0.032).

Moreover, after exposure for 28 days, there was a borderline-significant 14.1-percent reduction in Ki-67 levels in the atorvastatin arm (median level: 1.70; p=0.056).

Median levels of prostate-specific antigen (PSA) were significantly comparable between the placebo and atorvastatin arms (–0.2 vs –0.4 ng/mL; difference, –0.2 ng/mL; p=0.2). While treatment duration had no effect on PSA levels, atorvastatin was significantly superior among high-grade cases (p=0.024).

The treatment had no significant effect on the combined inflammation score, as well as on inflammation on separate tissue compartments. In high-grade cases, atorvastatin significantly suppressed intraprostatic inflammation.

Overall, the findings showed that while short-term, high-dose intervention with atorvastatin was well-tolerated, it yielded no significant beneficial effects, except in patients with high-grade malignancies. On the other hand, extended exposure successfully reduced prostate cancer proliferation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.